Patients with prostate cancer are benefiting from newly available treatments and strategies for managing their disease. And men at risk for prostate cancer can now learn more about the potential risks and benefits of screening for the disease.

Newly Approved Drugs for Prostate Cancer – Learn about new drug therapies recently approved for treating men with advanced prostate cancer.

• Cabazitaxel Drug Information Summary
• Sipuleucel-T (Provenge) Drug Information Summary

Other Interventions – Read the latest information on prostate cancer screening and recent developments in managing prostate cancer through active surveillance, radiation therapy, and surgery.

• For an overview of tests commonly used to screen for prostate cancer, see the Prostate Cancer Screening (PDQ®) summary.
• The NCI Cancer Bulletin features the following articles:
  • Denosumab Keeps Bones Strong during Prostate Cancer Treatment
  • Physicians Urged to Consider Active Surveillance in Prostate Cancer  
  • Adding Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer
  • Minimally Invasive Prostate Cancer Surgery Shows Benefits, Shortcomings
• A robotic radical prostatectomy is a surgeon-directed robotic procedure used as a minimally invasive approach to prostate cancer surgery – see the NCI Benchmarks article and video.

Prostate cancer is a complex disease, and despite its prevalence, much remains to be learned about its causes and the mechanisms by which it grows and spreads throughout the body. Fortunately, some of prostate cancer’s secrets are beginning to be revealed.

• The PDQ® cancer information summary Genetics of Prostate Cancer, intended mainly for health care professionals, discusses family history and other risk factors for prostate cancer, screening and risk modification for hereditary prostate cancer screening, and other issues.  
• The NCI Cancer Bulletin features the following articles:
  • Genome Studies Start to Unravel Prostate Cancer’s Complexity
  • Prostate Tumor Microenvironment Found to Change Immune Cell's Function
  • Many Prostatectomy Patients Face Low Risk of Prostate Cancer Death
  • How Gene Fusions May Occur in Prostate Cancer
  • Circulating Tumor Cells Detected in Patients with Localized Cancers

• NCI conducts and sponsors cutting-edge research on the causes, risk factors, genetics, and biochemical interactions that lead to the development and spread of prostate cancer. Likewise, a substantial number of NCI’s clinical studies are devoted to better screening and treatment of the disease, as well as to more effective strategies for preventing men from getting it in the first place.

  • A Snapshot of Prostate Cancer – Highlights from NCI’s recent research investments in prostate cancer, including:
    • International Prostate Screening Trials Evaluation Group (IPSTEG) – This group is developing and implementing a plan to jointly analyze data from randomized trials of prostate-specific antigen (PSA) screening for prostate cancer in order to build a larger, more informative database.
  • Breast and Prostate Cancer Cohort Consortium (BPC3) – BPC3 investigators pool data and biospecimens from large groups of patients to conduct genetics and epidemiology research in prostate and breast cancer.   
  • The following lists of NCI-sponsored prostate cancer clinical trials can be refined by location, stage of disease, drug, and other features.
    • prostate cancer prevention clinical trials
    • prostate cancer screening clinical trials
    • prostate cancer treatment clinical trials

• Prostate Cancer Home Page – A collection of resources about prostate cancer treatment, screening, genetics, prevention, research, statistics, and clinical trials.
• What You Need To Know About™ Prostate Cancer – An easy-to-understand booklet on prostate cancer.
• Understanding Prostate Changes: A Health Guide for Men – A patient-education booklet discussing signs of non-cancerous prostate conditions, along with cancer and screening tests.
• Cancer Stat Fact Sheet: Cancer of the Prostate – A collection of statistics on prostate cancer, including figures on risk, annual incidence, overall prevalence, mortality, and survival, from NCI’s Surveillance, Epidemiology and End Results (SEER) Program.